Literature DB >> 29031310

In a bad place: Carers of patients with head and neck cancer experiences of travelling for cancer treatment.

Myles Balfe1, Kieran Keohane2, Katie O' Brien3, Rachael Gooberman-Hill4, Rebecca Maguire5, Paul Hanly6, Eleanor O' Sullivan7, Linda Sharp8.   

Abstract

PURPOSE: To explore the effect that treatment-related commuting has on carers of patients with head and neck cancer.
METHOD: Semi-structured interviews, thematically analysed, with 31 carers.
RESULTS: Treatment-related commuting had a considerable impact on carers of patients with head and neck cancer, both in practical terms (economic costs, disruption) and also in psychological terms. Many carers of patients with head and neck cancer described becoming distressed by their commute. Some carers from large urban cities appeared to have hidden commuting burdens. Some carers respond to commuting stress by 'zoning out' or becoming 'like zombies'.
CONCLUSIONS: Treatment-related travel for head and neck cancer can have significant practical and psychological impacts. Health professionals should be aware of the impacts that commuting can have on head and neck caregivers. Health services may be able to take practical steps, such as providing subsidized parking, to address head and neck carergivers' difficulties.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Caregiving; Carer; Commuting; Head and neck cancer; Qualitative; Travel; Treatment

Mesh:

Year:  2017        PMID: 29031310     DOI: 10.1016/j.ejon.2017.07.001

Source DB:  PubMed          Journal:  Eur J Oncol Nurs        ISSN: 1462-3889            Impact factor:   2.398


  2 in total

1.  Assessment of Parking Fees at National Cancer Institute-Designated Cancer Treatment Centers.

Authors:  Anna Lee; Kanan Shah; Fumiko Chino
Journal:  JAMA Oncol       Date:  2020-08-01       Impact factor: 31.777

Review 2.  Caregiver Burden in Multiple Sclerosis: Recent Trends and Future Directions.

Authors:  Rebecca Maguire; Phil Maguire
Journal:  Curr Neurol Neurosci Rep       Date:  2020-05-22       Impact factor: 5.081

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.